← Eichor
Study identifier: NCT05955326 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Condition: Acute Cerebral Ischemia  ·  Sponsor: Pharmazz, Inc.

PhasePhase 4
Planned participants160
Who can joinAll sexes, 18 Years to 78 Years
Healthy volunteersNo

About this study

This is a prospective, multicenter, randomized, double-blind, parallel, phase IV study designed to evaluate the safety and efficacy of sovateltide (PMZ-1620, IRL-1620) as a potential treatment for cerebral ischemic stroke.

This description comes directly from the study's public registry record.

Talk to the study team

Dharmesh Shah, Dr.  ·  +91(120)256-9779  ·  dharmesh.shah@pharmazz.com

Always discuss trial participation with your own doctor first.

Locations (6)

Guntur Medical College and Government General HospitalGuntur, Andhra Pradesh, IndiaRecruiting
Lalitha Super Specialities Hospital Pvt. Ltd.Guntur, Andhra Pradesh, IndiaRecruiting
Radiant Superspeciality HospitalAmravati, Maharashtra, IndiaRecruiting
Government Medical College and attached HospitalsKota, Rajasthan, IndiaRecruiting
KG Hospital and Post Graduate Medical InstituteCoimbatore, Tamil Nadu, IndiaRecruiting
Maharani Laxmibai Medical CollegeJhānsi, Uttar Pradesh, IndiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05955326